E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Ovarian dysgenesis and related hypogonadism caused by Turner syndrome |
Ovariedysfunktion og relateret hypogonadisme forårsaget af Turner syndrom |
|
E.1.1.1 | Medical condition in easily understood language |
Failure of the ovaries and related decreased production of female sex hormone, estrogen, caused by the congenital Turner syndrome |
Manglede funktion af æggestokkene og dermed relateret nedsat produktion af kvindelig kønshormon, østrogen, forårsaget af det medfødte Turner syndrom |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10045181 |
E.1.2 | Term | Turner's syndrome |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. Find the equipotency for different estradiol regimens, oral versus transdermal (TD) route of administration, using different estradiol-dependent surrogate markers.
|
1. Finde ækvipotens for forskellige østradiolregimer, oral versus transdermal (TD) administrationsvej, ved hjælp af forskellige østradiol-afhængige surrogatmarkører.
|
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Ikke anvendelig |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For participants with TS: - Diagnosis of TS regardless of karyotype - Age 18-50 years - Receives estrogen treatment in advance
|
For deltagerne med TS: - Diagnose med TS uanset karyotype - Alderen 18-50 år - Modtager behandling med østrogen i forvejen |
|
E.4 | Principal exclusion criteria |
- Active systemic chronic diseases - Known with or with suspicion of breast cancer - Known or suspected estradiol-dependent tumors (endometrial cancer or similar) - Untreated endometrial hyperplasia - Current or past venous thromboembolism - Acute or previous liver disease, where liver enzymes are still elevated by at least a factor of 3 - Known hypersensitivity to active substances or excipients in any of the used medicines - Pregnancy |
- Aktive systemiske kroniske sygdomme - Kendt med eller med mistanke om brystkræft - Kendt med eller med mistanke om østradiolafhængige tumorer (endometriecancer eller lignende) - Ubehandlet endometrie hyperplasi - Nuværende eller tidligere venøs tromboembolisme - Akut eller tidligere leversygdom, hvor leverenzymerne stadig er forhøjet med mindst en faktor på 3 - Kendt overfølsomhed overfor aktive stoffer eller hjælpestoffer i nogen af de anvendte lægemidler - Graviditet |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Dose equivalence for tablet and gel therapy, which is the dosage that leads to the same levels of sex hormones in the blood of the participants. |
Dosisækvivalens for tablet og gelbehandling i form af den dosering, der fører til samme værdier af kønshormoner i blodet hos deltagerne. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Participants with Turner syndrome will have blood tests with female sex hormones taken on day 0 and day 14 of the study. |
Deltagerne med Turner syndrom vil få taget blodprøver med kvindelig kønshormoner på dag 0 og dag 14 i undersøgelsen. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Yes |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end when the last participants has gone through the last examination day (after the two times two weeks of treatment with one week in between without medicine) blood tests are taken on the last examination day 35. |
Forsøget afsluttes, når den sidste deltager har gennemgået den sidste undersøgelsesdag (efter to gange to ugers behandling og en uge i mellem uden behandling) tages blodprøver på sidste undersøgelsesdag 3). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |